ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1436

Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study
Abstract Number: 1684

Increase in Emergency Department Visits and Hospitalizations, Decrease in Outpatient Visits Following Transition to Adult Rheumatologic Care
Abstract Number: 0554

Increased Burden of Painful Arthritis and Rheumatism Following the Chikungunya Epidemic 2006: India Rural Population Survey 2018
Abstract Number: 0191

Increased Frequency of Lower Limb Arterial Obstruction in Rheumatoid Arthritis
Abstract Number: 1182

Increased Prevalence of Carotid Atherosclerosis in Postmenopausal Women with Rheumatoid Arthritis: A Case Control Study
Abstract Number: 1858

Increased Proportion of TH17, TH22 and TC17 Cells and the Correlation to IL-22 and Clinical Parameters in Patients with Ankylosing Spondylitis from Northern Sweden
Abstract Number: 0382

Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis
Abstract Number: 0756

Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive
Abstract Number: 0338

Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis
Abstract Number: 1220

Increased Serum Levels of Circulating Vimentin and Citrullinated Vimentin Are Differently Regulated by Tocilizumab and Methotrexate Monotherapies in Rheumatoid Arthritis
Abstract Number: 0057

Increased Susceptibility to Measles in Patients from Central America and Mexico in a U.S. Rheumatology Clinic
Abstract Number: 1721

Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Abstract Number: 0478

Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program
Abstract Number: 0604

Increasing the Rate of Pneumococcal Vaccination in an Academic Rheumatology Outpatient Clinic
Abstract Number: 0887

Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].